Abstract
Hidradenitis suppurativa (HS) is a chronic, follicular occlusive, inflammatory skin condition. It affects the intertriginous skin areas of the axillary, groin, perianal, perineal, and inframammary regions. It presents as recurrent, inflamed nodules and abscesses, draining sinus tracts and bands of severe scar formation. It is associated with pain, bad odor, discharge, and disfigurement. Severity of the disease is staged clinically according to the Hurley staging system. Treatment should include avoidance of trauma to the skin, discontinuation of smoking, and losing weight. The affected region should be washed by antiseptics. In addition, pain should be managed; topical clindamycin cream and topical resorcinol may be applied. Other treatments are intralesional corticosteroid injections and oral tetracyclines. Systemic glucocorticoids, cyclosporine, or the TNF-alpha inhibitors—adalimumab and infliximab—are sometimes tried. In severe cases cold knife or CO2 laser excision of lesions may be used to unroof the lesions, nodules, or sinuses. Wide excision is appropriate for advanced disease. Extensive excisions with skin grafts are also used.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
References
Sellheyer K, Krahl D. “Hidradenitis suppurativa” is acne inversa! An appeal to (finally) abandon a misnomer. Int J Dermatol. 2005;44:535.
Kouris A, Platsidaki E, Christodoulou C, et al. Quality of life and psychosocial implications in patients with hidradenitis suppurativa. Dermatology. 2016;232:687.
Garg A, Kirby JS, Lavian J, et al. Sex- and age-adjusted population analysis of prevalence estimates for hidradenitis suppurativa in the United States. JAMA Dermatol. 2017;153:760.
von der Werth JM, Williams HC. The natural history of hidradenitis suppurativa. J Eur Acad Dermatol Venereol. 2000;14:389.
Faivre C, Villani AP, Aubin F, et al. Hidradenitis suppurativa (HS): an unrecognized paradoxical effect of biologic agents (BA) used in chronic inflammatory diseases. J Am Acad Dermatol. 2016;74:1153.
Riis PT, Vinding GR, Ring HC, Jemec GB. Disutility in patients with hidradenitis suppurativa: a cross-sectional study using EuroQoL-5D. Acta Derm Venereol. 2016;96:222.
Hurley HJ. Axillary hyperhidrosis, apocrine bromhidrosis, hidradenitis suppurativa, and familial benign pemphigus: surgical approach. In: Roenigk RK, Roenigk HH, editors. Dermatologic surgery. New York: Marcel Dekker; 1989. p. 729.
von Laffert M, Stadie V, Wohlrab J, Marsch WC. Hidradenitis suppurativa/acne inversa: bilocated epithelial hyperplasia with very different sequelae. Br J Dermatol. 2011;164:367.
Danby FW, Margesson LJ. Hidradenitis suppurativa. Dermatol Clin. 2010;28:779.
Shuja F, Chan CS, Rosen T. Biologic drugs for the treatment of hidradenitis suppurativa: an evidence-based review. Dermatol Clin. 2010;28:511.
Blok JL, Li K, Brodmerkel C, et al. Ustekinumab in hidradenitis suppurativa: clinical results and a search for potential biomarkers in serum. Br J Dermatol. 2016;174:839.
Author information
Authors and Affiliations
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 2019 Springer International Publishing AG, part of Springer Nature
About this chapter
Cite this chapter
Bornstein, J. (2019). Hidradenitis Suppurativa. In: Bornstein, J. (eds) Vulvar Disease. Springer, Cham. https://doi.org/10.1007/978-3-319-61621-6_48
Download citation
DOI: https://doi.org/10.1007/978-3-319-61621-6_48
Publisher Name: Springer, Cham
Print ISBN: 978-3-319-61620-9
Online ISBN: 978-3-319-61621-6
eBook Packages: MedicineMedicine (R0)